Merck Licenses China Origin KRAS G12D Molecular Glue

Company Merck; SciBrunch Therapeutics Event Type Exclusive License Modality Small Molecule Molecular Glue Asset SPR2015 Target KRAS G12D (Active/ON-State) Disease Area Oncology (Pancreatic and Colorectal Cancer) Summary Merck acquired exclusive worldwide development, manufacturing and commercialization rights to SPR2015 from Shanghai-based SciBrunch Therapeutics. Merck will pay…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline